Search
FDA to Phase Out 'Animal Testing Principle' for Monoclonal Antibodies, Boosting US Pharma Stocks by Over 16%
2025-04-11 /
Read about 0 minute
Author：小编
The Food and Drug Administration (FDA) has unveiled plans to progressively phase out animal testing in the development of monoclonal antibodies and other medications, transitioning instead to more human-centric and efficient research methods, including computer modeling. This decision has sparked a notable decline in the Hang Seng Innovative Medicines Index and associated ETFs, while simultaneously elevating the share prices of AI-driven pharmaceutical firms like Schrödinger and Recursion Pharmaceuticals. The capital market exhibits a favorable view towards the substitution of animal testing with AI technology.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
